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Abstract 
To inform the level of attention to be given by antiretroviral therapy (ART) programs to HIV drug 
resistance (HIVDR), we used an individual-level model to estimate its impact on future AIDS deaths, 
HIV-incidence and ART program costs in sub-Saharan Africa (SSA) for a range of program situations.  
We applied this to SSA through the Spectrum-Goals model.  In a situation in which current levels of 
pre-treatment HIVDR are over 10% (mean 15%), 16% of AIDS deaths (890,000 deaths) , 9% of new 
infections (450,000) and 8% ($6.5 billion) of ART program costs in SSA in 2016-2030 will be 
attributable to HIVDR.   
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Introduction    
UNAIDS has set the ambitious global goal of increasing  the number of people on antiretroviral 
therapy (ART) who have viral load suppression, with the dual aim of eliminating  AIDS as a public 
health threat and ending new infections by 2030 (1).  Since scale-ƵƉŽĨZdŝŶƚŚĞĞĂƌůǇ ? ? ? ? ?Ɛ ?ůĞǀĞůƐ
of HIV drug resistance (HIVDR) have been increasing gradually (2,3) and HIVDR has been shown to 
compromise the effect of commonly used drug regimens (4,5).  If levels of HIVFT are allowed to 
further increase, they may compromise the ability to reach the UNAIDS goal of 90% of all people 
taking ART having suppressed viral load.  Moreover, high levels of HIVDR are likely an indication of 
gaps in ART service delivery, such as sub-optimal retention on ART, poor population-level adherence 
to ART, high levels of unknown treatment outcomes and stock outs of antiretroviral drugs, and signal 
need for programmatic improvements.  The actual and potential impact of HIVDR has not previously 
been estimated.  We used a model of HIV / ART programs to estimate the impact of drug resistance 
from 2016-2030 in key outcomes of AIDS deaths, new infections, and ART program costs.  
Subsequently, using the Spectrum Goals model, we used these estimates of impact to estimate the 
absolute level of impact in sub-Saharan Africa as a whole (6). 
 
Methods 
 
Modelling Approach 
We use the HIV Synthesis Model, an individual-based simulation model of HIV transmission, 
progression and the effect of ART, considering specific drugs and resistance mutations.   The model 
has been described in detail (e.g. 7, 8).   For this project we initially based the demographics of the 
population studied and HIV epidemic and ART program features around those for Malawi, although 
by sampling parameters relating to sexual behavior, HIV testing, ART adherence, rate of treatment 
interruption, ART monitoring strategy, switch rate after first-line regimen failure we generated 
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diverse situations likely to reflect a range of settings in SSA in respect of aspects, such as HIV 
prevalence, ART uptake, HIV incidence and transmitted HIVDR.   We restricted attention to situations 
(i.e. model runs) in which HV prevalence was between 8% and 30% in 1999 and between 8% and 
25% in 2004, and also to those in which the level of HIVDR amongst ART naïve treatment initiators 
was below 20% in 2014 as evidence based on data to this date suggests levels are below this level (9-
11).    
 
For each setting situation generated, we look at the projected outcomes from 2016 to 2030 under 
the assumption of (i) no change in the rates of resistance acquisition and transmission (indicated as 
with HIV drug resistance scenario in Table 1), and (ii) a hypothetical (i.e. counter-factual) scenario in 
which resistant virus disappears in those in whom it is present (leaving all people with drug sensitive 
virus only) and there is no new acquisition or transmission of resistant virus (without further HIV 
drug resistance scenario).   We assume that from 2016 viral load monitoring is introduced (using the 
WHO criteria of a confirmed value > 1000 copies/mL to define failure (12)), that efavirenz with 
tenofovir and emtricitabine/lamivudine remains the first line regimen for the duration, with 
atazanavir plus zidovudine and emtricitabine or lamivudine used in second line regimens, and 
darunavir plus dolutegravir plus tenofovir plus emtricitabine or lamivudine as third line.  The rate of 
switching to a 2nd line regimen after 1st line failure is increased from 0.05-0.2 per 3 months before 
2016 to 0.5 per 3 months after 2017. This was done so that we could look at the impact of drug 
resistance in the context of close to an optimal switching strategy  ? our estimates of health impact 
are conservative in this respect.  We present the median and 90% range over situations (model runs) 
for the impact of drug resistance on HIV incidence, AIDS deaths and ART program costs.   
 
Having used the HIV Synthesis model to estimate the impact of HIVDR we then extrapolated this to 
sub-Saharan Africa as a whole by applying the proportion of AIDS death, new infections and ART 
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costs attributable to HIVDR to the fast-track projected estimates of these obtained using the 
Spectrum Goals model (6). 
 
Modelling of ART and HIVDR  
HIVDR is modelled in terms of the presence or absence of mutations specific to the drugs in use.   
Distinction is made for each mutation as to whether it is present only in low abundance, and thus 
assumed non-transmissible, or if it is present in majority virus.  The probability of selection of drug-
resistant virus among people on ART is determined by the number of active drugs in the regimen 
(determined by presence of relevant resistance mutations), viral load, and the ŝŶĚŝǀŝĚƵĂůƐ ?ĐƵƌƌĞŶƚ
ART adherence.   Mutations acquired while on ART are lost from majority virus (at a mutation-
specific rate) after the drug selecting for it is discontinued, although these mutations remain in 
minority virus.  Mutations present in minority virus re-emerge in majority virus when one of the 
corresponding drugs is started.  The probability of transmission of HIV from a condomless sex 
partner depends on the viral load in the source partner.  The presence of drug resistance in in the 
partner does not directly influence the risk of transmission, only via any effect on viral load.  For a 
newly infected person, the probability that the source partner has resistant virus in the majority 
circulating virus is determined by the prevalence of resistance among those with HIV having 
condomless sex.  Not all resistance mutations present in majority virus in the source partner are 
established in the circulating virus of the newly infected person.   The probability of transmission of 
drug resistance mutations is mutation-specific.   Once virus with a mutation is transmitted and 
established in the new host, there is a tendency for a loss of drug-resistant mutation from majority 
virus over time, again mutation-specific.   A series of comparisons of model outputs with observed 
data for a range of ART-related variables is shown in the Supplementary material.   
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Results 
We generated 2500 HIV epidemic /program situations in total.   The characteristics of these 
situations in 2015 are reported as the median (5%-95% range): HIV prevalence (8% (4%-17%), HIV 
incidence (0.36 per 100 person years (0.12-1.26), proportion diagnosed (86% (68%-93%), proportion 
on ART (64% (47%-78%)).   
 
Table 1 shows the outcomes projected for 2016 ?2030 for scenarios with HIV drug resistance and 
without further HIV drug resistance.  Table 1 also shows the percentage or absolute difference 
between these scenarios, which indicates the impact that HIVDR is projected to have over 2016-
2030.  This is shown separately in the context of setting situations with current level of pre-
treatment HIVDR (PDR) < 10% and over 10%.   In the former case, we estimate a 6% lower viral 
suppression rate in those on ART, 13% higher number of AIDS deaths per year, 7% higher HIV 
incidence, 6% higher ART costs are all attributable to HIVDR.   In settings with current level of PDR > 
10%, an 8% lower viral suppression rate in those on ART, 16% higher number of AIDS deaths per 
year, 9% higher HIV incidence and 8% higher ART costs are attributable to HIVDR.  The median and 
90% range over model runs presented conveys the uncertainty and variability across settings in 
these estimates of attribution. 
Table 2 shows the projected average impact of HIV drug resistance on AIDS deaths, new infections 
and ART costs in sub-Saharan Africa between the present and 2030 using the Spectrum Goals fast-
track modelling.  Results indicate that in a situation where pre-treatment drug resistance levels are 
generally below 10% there is still a substantial impact of drug resistance, being responsible for an 
estimated 710,000 AIDS deaths, 380,000 new infections and $5.0 billion extra ART costs by 2030.  If 
levels of pre-treatment drug resistance are over 10% the impact is greater with an estimated 
890,000 AIDS deaths, 450,000 new infections and $6.5 billion extra ART costs by 2030 attributable to 
HIVDR. 
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Discussion  
Recently, elevated levels of NNRTI drug resistance among ART-naïve individuals have been observed 
in several low and middle income countries, including Angola (14%), Botswana (8%), Cuba (8%), 
Mexico (10%), Papua New Guinea (16%) and South Africa (14%) (9-11). The levels of NNRTI 
resistance reach almost 40% among ART starters with prior ARV exposure (9, 11).   Our estimates 
indicate that, even in settings where pre-treatment HIVDR levels are relatively lower (<10%), 
resistant virus is nevertheless responsible for a significant extra burden of new AIDS deaths and 
additional costs.   Results underscore the need for countries to follow WHO recommendations to 
both monitor levels of HIVDR and ART program factors (or early warning indicators of HIVDR) 
associated with its emergence and make any necessary program changes to reduce the rate with 
which resistance emerges, accumulates and is subsequently transmitted (12-14).   We convey 
uncertainty and variability between settings in the impact of HIVDR through our 90% range over 
model runs.  These bounds suggest that there is more uncertainty and variability around the impact 
of HIVDR on new infections than around the impact on AIDS deaths and costs.   
It is important to emphasize that our estimates of the impact of resistance are based on there being 
no change in the regimens in use or introduction of baseline drug resistance testing.   While our 
modelling shows the importance and impact of HIVDR in determining program outcomes if this 
current situation continues, it does not address the practical question of what should be the 
response in countries to finding of high levels of pre-treatment HIVDR and what level of HIVDR 
should trigger a public health response.  Previous work has suggested a key role for introducing viral 
load monitoring, if not available (8), in response to high levels of transmitted HIV drug resistance.  In 
addition, increasing the frequency of viral load monitoring and using a lower threshold to define 
failure could be another response to high levels of transmitted drug resistance.  Other potential 
future options include transitioning from efavirenz-based to dolutegravir-based first-line regimens, 
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and possibly in some areas use of individuallevel drug resistance testing before or soon after the 
start of ART.    
Although we show that drug resistance is a serious concern, it should not be used as a reason against 
expanding ART use to all individuals infected with HIV both for treatment and prevention, as is now 
recommended by WHO (12) ?DŽĚĞůůŝŶŐŚĂƐƐŚŽǁŶƚŚĂƚƚŚĞďĞŶĞĨŝƚƐŽĨ ?dƌĞĂƚůů ?ĨĂƌŽƵƚǁĞŝŐŚƚŚĞ
potential risks of HIVDR; in fact, while we should expect to see an increased proportion of ART 
initiators with drug resistant virus, overall HIV incidence is predicted to decline  (7, 15).  
It is important to note in studying  Table 1 that any comparisons across the < 10% and > 10% pre-
treatment HIVDR situations should be interpreted with caution as such comparisons not only reflect 
the effect of HIVDR but also the  presence of confounding.  For example, settings in which 
population-level adherence to ART is lower tend to have higher levels of pre-treatment HIVDR, but 
also there are direct effects of adherence on mortality, viral suppression, and HIV incidence which 
are not mediated by drug resistance.  Thus there is confounding by the common cause of poor 
adherence.  A further caveat is that the estimates in Table 1 are based on adults only.  While fewer 
children are being infected, amongst HIV positive children there are often high levels of acquired and 
transmitted drug resistance.  In this respect, our results under-estimate the full impact of HIVDR. 
In summary, our results indicate that HIVDR inevitably causes attenuation of the potential full health 
benefits of ART and adds cost to the programs.  Whilst we cannot remove drug resistance 
completely, we can take measures to minimize its impact on health and ART program costs.  To 
achieve the UNAIDS targets of 90-90-90 by 2020 and the elimination of AIDS as a public health threat 
by 2030, not only do millions of people need to be started and retained on ART, but the quality of 
service delivery in many countries needs be strengthened and routine HIVDR surveillance and 
response must become an integral part of ART programs. 
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Table 1.  Impact that HIV drug resistance (HIVDR) is projected to have between 2016 and 2030 (mean and, for effect of drug resistance, median; 90% range over model 
runs / situations).  This is the projected average impact in the context of low income settings in sub-Saharan Africa with and adult population size 10 million.  PDR  ? pre-
treatment drug resistance.    
+ in context of country with adult population size of 10 million.  * discounted at 3% per year     
&
 Costs of  ARV drugs  (incl  20% for supply chain) 1
st
 line $120, 2
nd
 line $343, 
3
rd
 line  $962.  Other unit costs are shown in Supplementary Methods.  
Scenario until 
2030 
% of those on ART 
who have viral load 
< 1000 cps/mL  
AIDS deaths + HIV incidence (adults 
15-49) / 100 person 
years  
Cost of 1
st
 line 
ART 
+ 
* 
& 
Cost of 2
nd
 line
+ 
* 
&
 
Cost of 3
rd
 line 
+ 
* 
&
 
Overall ART cost 
+ 
* 
&
  
Current level of PDR < 10% (mean ~ 5.7%) 
(i) With HIVDR  89% 
 
16,000 per year 
 
0.19 
 
$50m $21m $1.0m $72m 
 
(ii) Without 
further  HIVDR 
95% 
 
14,000 per year 
 
0.17 
 
$55m $12m $0.7m $68m 
 
Effect of HIVDR 
 
6%  
Median 6% (5% - 7%) 
lower viral 
suppression rate in 
those on ART 
13%  
Median 12% 
(3% - 23%) 
attributable to  
HIVDR 
7%  
Median 8% (0% - 
23%)  
HIV incidence 
attributable to  HIVDR 
Lower cost of 1
st
 
line drugs 
Higher cost of 2
nd
 
line drugs 
Higher cost of 
3
rd
 line drugs 
6%  
Median 6% (2% - 9%) 
of ART costs 
attributable to HIVDR 
Current level of PDR > 10% (mean ~ 15%) 
(i) With HIVDR 85% 
 
26,000 per year 
 
0.48 
 
$71m $38m $2.0m $111m 
 
(ii) Without 
further  HIVDR 
93% 
 
22,000 per year 
 
0.43 
 
$79m $22m $1.4m $102m 
 
Effect of HIVDR 
 
8%  
Median 8% (6% - 
10%) lower viral 
suppression rate in 
those on ART 
16%  
Median 16% 
(7% - 25%) 
attributable to  
HIVDR   
9%  
Median 9% (0% - 
26%) 
HIV incidence 
attributable to  HIVDR 
Lower cost of 1
st
 
line drugs 
Higher cost of 2
nd
 
line drugs 
Higher cost of 
3
rd
 line drugs 
8%  
Median 8% (4% - 
11%) 
of ART costs 
attributable to HIVDR  
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Table 2.   Projected impact of HIV drug resistance (HIVDR) on AIDS deaths, new infections and ART costs in 
sub-Saharan Africa between 2016 and 2030.   Using the Spectrum Goals model estimates (6), by applying the 
impact of drug resistance as estimated using the HIV Synthesis Model    
    
  
AIDS deaths 
 
New infections 
 
ART costs 
With HIVDR 
(Fast-track projections) 
5.6 million  5.1 million $  83 billion 
 
Current level of PDR < 10%  
Percentage attributable to 
HIVDR 
13%  
 
7%  
 
6%  
 
Amount attributable to HIVDR 710,000 380,000 $5.0 biillion 
 
Current level of PDR > 10%  
Percentage attributable to 
HIVDR 
16%  9%  
 
8%  
 
Amount attributable to HIVDR 890,000 450,000 $6.5 billion 
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